Remarkably, the prevalence of these auto-Abs in the adult general population remains stable until the age of 70 years (about 0.3% for auto-Abs neutralizing high concentrations of IFN and 1% for auto-Abs neutralizing low concentrations of IFNs), after which it increases sharply (reaching up to 4% and 7%, respectively, in individuals aged 80–85 years), consistent with the higher risk of life-threatening COVID-19 in the elderly population (Bastard et al., 2021a; Manry et al., 2022). The gene discussed is IFNA1; the disease is COVID-19.